MiMedx
-
Financial
MiMedx Announces That Its Second Quarter Revenue Exceeds The Guidance Range
MARIETTA, Ga., July 13, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More » -
Biologics
Scientific And Clinical Review Confirms Potential Of MiMedx dHACM Allografts For Regenerative Applications In Orthopedics
MARIETTA, Ga., June 15, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative…
Read More » -
MiMedx EpiFix® Receives Coverage From Kaiser Permanente
MARIETTA, Ga., May 4, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics…
Read More » -
Biologics
MiMedx Receives Innovative Technology Supplier of the Year Award from Vizient, Inc.
MARIETTA, Ga., May 1, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative…
Read More » -
Financial
MiMedx Announces Record Results For First Quarter Of 2017
MARIETTA, Ga., April 28, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics…
Read More » -
Biologics
MiMedx to Present at the European Wound Management Association Annual Conference
MARIETTA, Ga., April 24, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative…
Read More » -
Financial
MiMedx Announces 2016 Record Results
MARIETTA, Ga., Feb. 23, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue…
Read More » -
Financial
MiMedx Board of Directors Authorizes $10 Million Increase to the Company’s Share Repurchase Program
MARIETTA, Ga., Feb. 6, 2017 /PRNewswire/ — MiMedx Group, Inc. (MDXG), the leading regenerative medicine company utilizing human amniotic tissue and…
Read More » -
Hospitals
MiMedx Comments On FDA Decision Not To Finalize HCT/P Guidance Documents This Year
MARIETTA, Ga., Feb. 3, 2017 /PRNewswire/ — MiMedx Group, Inc. MDXG 2.31%, the leading regenerative medicine company utilizing human amniotic…
Read More » -
Hospitals
MiMedx Announces Preliminary Investigation Findings
MARIETTA, Ga., Dec. 27, 2016 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected…
Read More » -
Biologics
MiMedx EpiFix Receives Coverage From Aetna
MARIETTA, Ga., Dec. 27, 2016 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected…
Read More » -
Hospitals
Whistleblowers Claim MiMedx Group, Inc. Defrauded Investors in Lawsuit Filed by Halunen Law
December 15, 2016 MINNEAPOLIS–(BUSINESS WIRE)–The MiMedx Group (NASDAQ: MDXG) persistently inflated its quarterly revenue figures over several years, using a…
Read More » -
Financial
MiMedx Third Quarter 2016 Revenue Exceeds Upper End of Guidance
MARIETTA, Ga., Oct. 10, 2016 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes…
Read More » -
Hospitals
MiMedx Urges FDA To Reconsider Draft Guidances During Hearing
MARIETTA, Ga., Sept. 15, 2016 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected…
Read More » -
Biologics
MiMedx Announces Nationwide Launch of AmnioFill™
MARIETTA, Ga., Sept. 1, 2016 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes…
Read More »